Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer ; volume:25 ; number:9 ; day:17 ; month:8 ; year:2024 ; pages:1225-1237 ; date:9.2024
Current treatment options in oncology ; 25, Heft 9 (17.8.2024), 1225-1237, 9.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Bischoff, Hervé
Espié, Marc
Petit, Thierry
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-024-01252-x
- URN
-
urn:nbn:de:101:1-2412050703387.002507739797
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bischoff, Hervé
- Espié, Marc
- Petit, Thierry
- SpringerLink (Online service)
Other Objects (12)
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer